Compare Dr. Reddys with FDC LTD. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs FDC LTD. - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB FDC LTD. DR. REDDYS LAB/
FDC LTD.
 
P/E (TTM) x 21.8 17.4 125.1% View Chart
P/BV x 3.3 2.4 138.3% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DR. REDDYS LAB   FDC LTD.
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
FDC LTD.
Mar-18
DR. REDDYS LAB/
FDC LTD.
5-Yr Chart
Click to enlarge
High Rs2,875319 901.3%   
Low Rs1,888164 1,151.2%   
Sales per share (Unadj.) Rs930.261.6 1,509.0%  
Earnings per share (Unadj.) Rs117.49.9 1,180.2%  
Cash flow per share (Unadj.) Rs185.812.0 1,552.6%  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs844.473.2 1,154.1%  
Shares outstanding (eoy) m166.07174.40 95.2%   
Bonus/Rights/Conversions ESOPBB-  
Price / Sales ratio x2.63.9 65.3%   
Avg P/E ratio x20.324.3 83.6%  
P/CF ratio (eoy) x12.820.2 63.5%  
Price / Book Value ratio x2.83.3 85.4%  
Dividend payout %17.00-   
Avg Mkt Cap Rs m395,49642,118 939.0%   
No. of employees `00022.05.5 397.1%   
Total wages/salary Rs m33,5622,167 1,549.0%   
Avg. sales/employee Rs Th7,032.81,943.7 361.8%   
Avg. wages/employee Rs Th1,527.9391.7 390.0%   
Avg. net profit/employee Rs Th887.7313.7 283.0%   
INCOME DATA
Net Sales Rs m154,48210,751 1,436.9%  
Other income Rs m3,375510 662.3%   
Total revenues Rs m157,85711,260 1,401.9%   
Gross profit Rs m31,7822,267 1,402.0%  
Depreciation Rs m11,348351 3,229.4%   
Interest Rs m88914 6,350.0%   
Profit before tax Rs m22,9202,411 950.6%   
Minority Interest Rs m0-5 0.0%   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,858671 574.8%   
Profit after tax Rs m19,5001,735 1,123.9%  
Gross profit margin %20.621.1 97.6%  
Effective tax rate %16.827.8 60.5%   
Net profit margin %12.616.1 78.2%  
BALANCE SHEET DATA
Current assets Rs m111,1017,213 1,540.4%   
Current liabilities Rs m58,9732,104 2,803.3%   
Net working cap to sales %33.747.5 71.0%  
Current ratio x1.93.4 54.9%  
Inventory Days Days7954 145.6%  
Debtors Days Days9428 339.8%  
Net fixed assets Rs m101,2456,865 1,474.8%   
Share capital Rs m830175 473.7%   
"Free" reserves Rs m139,40612,586 1,107.6%   
Net worth Rs m140,23612,761 1,098.9%   
Long term debt Rs m22,0006 366,666.7%   
Total assets Rs m224,65615,041 1,493.6%  
Interest coverage x26.8173.2 15.5%   
Debt to equity ratio x0.20 33,365.7%  
Sales to assets ratio x0.70.7 96.2%   
Return on assets %9.111.6 78.0%  
Return on equity %13.913.6 102.3%  
Return on capital %14.919.0 78.8%  
Exports to sales %012.3 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA1,327 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m88,6731,889 4,694.6%   
Fx outflow Rs m19,1040-   
Net fx Rs m69,5691,889 3,683.2%   
CASH FLOW
From Operations Rs m28,7041,498 1,915.6%  
From Investments Rs m-7,727201 -3,842.4%  
From Financial Activity Rs m-21,326-1,694 1,258.7%  
Net Cashflow Rs m-31410 -3,048.5%  

Share Holding

Indian Promoters % 25.5 68.9 37.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 4.7 114.9%  
FIIs % 35.3 7.5 470.7%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 19.0 80.5%  
Shareholders   75,885 23,730 319.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   GSK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  IPCA LABS  JUBILANT LIFE SCIENCES  

Compare DR. REDDYS LAB With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher; Tata Steel & Bajaj Finance Top Gainers(12:30 pm)

Share markets in India are presently trading on a positive note, tracking gains in global peers. US President Donald Trump said he did not want war.

Related Views on News

FDC LTD. Announces Quarterly Results (1QFY20); Net Profit Up 2.4% (Quarterly Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

For the quarter ended June 2019, FDC LTD. has posted a net profit of Rs 523 m (up 2.4% YoY). Sales on the other hand came in at Rs 3 bn (up 17.9% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

FDC LTD. Announces Quarterly Results (4QFY19); Net Profit Up 6.8% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, FDC LTD. has posted a net profit of Rs 337 m (up 6.8% YoY). Sales on the other hand came in at Rs 3 bn (down 0.6% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

FDC LTD. 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of FDC LTD. for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of FDC LTD.. Also includes updates on the valuation of FDC LTD..

FDC LTD. Announces Quarterly Results (3QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Feb 15, 2019 | Updated on Feb 15, 2019

For the quarter ended December 2018, FDC LTD. has posted a net profit of Rs 437 m (up 2.5% YoY). Sales on the other hand came in at Rs 3 bn (up 1.4% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Sep 18, 2019 01:19 PM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - NOVARTIS COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS